Estrella Immunopharma Inc (ESLA)

$1.99 +0.06 (3.11%)
Market Cap 59.67M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 80,936
Avg Vol 337,426
Day's Range N/A - N/A
Shares Out 37.77M
Stochastic %K 29%
Beta 0.53
Analysts Strong Sell
Price Target $16.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
topstockalerts
topstockalerts Dec. 4 at 2:58 PM
Estrella Immunopharma said its CD19-targeted cancer therapy received clearance to advance into Phase II testing. An independent safety board recommended moving its STARLIGHT-1 trial into an expansion phase after a favorable safety review of EB103 for relapsed or refractory B-cell non-Hodgkin lymphoma. The Phase I dose-escalation stage showed no treatment-related serious adverse events in nine patients, many considered high risk, and the high-dose cohort achieved a 100% complete response rate at Month 1. Estrella called this a major milestone, noting EB103’s strong safety profile and full responses suggest it may overcome toxicity challenges that have historically limited CD19-targeted CAR-T therapies. The expansion phase will further evaluate safety and early efficacy at the recommended Phase II dose. $ESLA
0 · Reply
ProfitsBee
ProfitsBee Dec. 4 at 1:31 PM
$ESLA Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:15 PM
$ESLA there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
BellaC_Trader
BellaC_Trader Nov. 28 at 8:56 PM
$ESLA meme-adjacent vibes, if EV or energy Twitter grabs this you’ll see it instantly in the candles
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 17 at 8:53 PM
$CYPH -7%[-12%] $MIST 6%[17%] $ESLA -4%[-17%] $ONEG 4%[-58%] $VENU -4%[-20%] most notable movement into the final minutes of trading.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Pb1782
Pb1782 Nov. 4 at 2:51 PM
$ESLA
0 · Reply
StockScanners
StockScanners Nov. 4 at 2:05 AM
$ESLA keep watch if this holds above 2.77
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 11:07 PM
$ESLA
0 · Reply
Latest News on ESLA
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 1 day ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 4 weeks ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 6 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 6 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 9 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 10 months ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 10 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

topstockalerts
topstockalerts Dec. 4 at 2:58 PM
Estrella Immunopharma said its CD19-targeted cancer therapy received clearance to advance into Phase II testing. An independent safety board recommended moving its STARLIGHT-1 trial into an expansion phase after a favorable safety review of EB103 for relapsed or refractory B-cell non-Hodgkin lymphoma. The Phase I dose-escalation stage showed no treatment-related serious adverse events in nine patients, many considered high risk, and the high-dose cohort achieved a 100% complete response rate at Month 1. Estrella called this a major milestone, noting EB103’s strong safety profile and full responses suggest it may overcome toxicity challenges that have historically limited CD19-targeted CAR-T therapies. The expansion phase will further evaluate safety and early efficacy at the recommended Phase II dose. $ESLA
0 · Reply
ProfitsBee
ProfitsBee Dec. 4 at 1:31 PM
$ESLA Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:15 PM
$ESLA there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
BellaC_Trader
BellaC_Trader Nov. 28 at 8:56 PM
$ESLA meme-adjacent vibes, if EV or energy Twitter grabs this you’ll see it instantly in the candles
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 17 at 8:53 PM
$CYPH -7%[-12%] $MIST 6%[17%] $ESLA -4%[-17%] $ONEG 4%[-58%] $VENU -4%[-20%] most notable movement into the final minutes of trading.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Pb1782
Pb1782 Nov. 4 at 2:51 PM
$ESLA
0 · Reply
StockScanners
StockScanners Nov. 4 at 2:05 AM
$ESLA keep watch if this holds above 2.77
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 11:07 PM
$ESLA
0 · Reply
Pb1782
Pb1782 Nov. 3 at 9:16 PM
$ESLA
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 8:51 PM
$ESLA Strong action today..
0 · Reply
AlGo88
AlGo88 Nov. 3 at 7:44 PM
$ESLA nice
0 · Reply
mibulldog
mibulldog Nov. 3 at 6:54 PM
$ESLA Up 220% in last 3 months, positive results for clinical trial of EB103. Only 314 watching?? Need to get more eyes on this.
0 · Reply
_luke637
_luke637 Nov. 3 at 5:55 PM
$ESLA
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 4:24 PM
D. Boral Capital has adjusted their stance on Estrella Immunopharma ( $ESLA ), setting the rating to Buy with a target price of 16.
0 · Reply
hsfjhv
hsfjhv Nov. 3 at 3:01 PM
$ESLA where is everyone? 100% complete response (CR) rate at Month 1 in all evaluable patients treated
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 28 at 7:58 PM
$VRA 4%[20%] $DVLT 4%[0%] $FUSE 4%[21%] $ESLA 3%[10%] $CLIK 3%[-28%] most notable movement into the final minutes of trading.
0 · Reply
Stocksiren
Stocksiren Oct. 24 at 3:34 PM
$ESLA
0 · Reply
StockScanners
StockScanners Oct. 24 at 12:50 AM
$ESLA reached 2.37
0 · Reply
Stocksiren
Stocksiren Oct. 23 at 11:18 AM
$ESLA
0 · Reply
StockScanners
StockScanners Oct. 23 at 12:48 AM
$ESLA keep watch if this holds above 2.15
0 · Reply